Collegium Pharmaceutical Inc (COLL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Collegium Pharmaceutical Inc (Collegium) is a specialty pharmaceutical company that focuses on the development and commercialization of innovative drugs for treating patients suffering from pain. It develops products based on its DETERx platform technology. DETERx offers extended-release drug delivery, while protecting against common methods of abuse and tampering. The company's lead product, Xtampza ER is designed to provide adequate pain control. Its other products include Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy; and Nucynta IR for the management of acute pain severe enough to require an opioid analgesic. The company is headquartered in Stoughton, Massachusetts, the US.Collegium Pharmaceutical Inc Key Recent Developments
- Feb 23, 2023: Collegium Reports Fourth Quarter and Full-Year 2022 Financial Results
- Feb 06, 2023: Collegium Announces Fourth Quarter and Full Year 2022 Preliminary Financial Results
- Jan 04, 2023: Collegium Provides 2023 Financial Guidance
- Nov 03, 2022: Collegium Reports Third Quarter 2022 Financial Results
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company Financial Ratios
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Section 5 - Company’s Recent Developments
Section 6 - Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Teva Pharmaceutical Industries Ltd
- Societal CDMO Inc
- Shionogi Inc
- Purdue Pharma LP
- Mallinckrodt Plc
- Elite Pharmaceuticals Inc
- Cassava Sciences Inc
- Acura Pharmaceuticals Inc
- Societal CDMO Inc
- Shionogi Inc
- Purdue Pharma LP
- Mallinckrodt Plc
- Teva Pharmaceutical Industries Ltd
- Elite Pharmaceuticals Inc
- Acura Pharmaceuticals Inc
- Cassava Sciences Inc